Interferons, immunity and cancer immunoediting
The DOI matches its Crossref record; 118 of the 119 references it cites were found in a registry or an index.
Abstract
A clear picture of the dynamic relationship between the host immune system and cancer is emerging as the cells and molecules that participate in naturally occurring antitumour immune responses are being identified. The interferons (IFNs) - that is, the type I IFNs (IFNalpha and IFNbeta) and type II IFN (IFNgamma) - have emerged as central coordinators of tumour-immune-system interactions. Indeed, the decade-old finding that IFNgamma has a pivotal role in promoting antitumour responses became the focus for a renewed interest in the largely abandoned concept of cancer immunosurveillance. More recently, type I IFNs have been found to have distinct functions in this process. In this Review, we discuss the roles of the IFNs, not only in cancer immunosurveillance but also in the broader process of cancer immunoediting.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“a cytokine which promotes increased tumour immunogenicity and often used to assess T-cell activation31”
From Stromal senescence establishes an immunosuppressive microenvironment that drives tumorigenesis (2016) · cites this paper as [31]
Citations
Cites
1 retracted
Urisman, A., Molinaro, R. J., Fischer, N., Plummer, S. J., Casey, G., Klein, E. A., Malathi, K., Magi-Galluzzi, C., Tubbs, R. R., Ganem, D., et al. (2006) · PLoS Pathogens · doi:10.1371/journal.ppat.0020025 · Cited by 577 · cited 1×
“However, it remains unclear whether the tumour-suppressor functions of RNaseL depend on IFN”
BackgroundRetractedHanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516 · cited 1×
“Using a combination of histological and gene-expression analyses, Galon et al”
MethodCancer immunoediting: from immunosurveillance to tumor escape
Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., & Schreiber, R. D. (2002) · Nature Immunology · doi:10.1038/ni1102-991 · Cited by 5,393
Self-citationCancer genes and the pathways they control
Vogelstein, B., & Kinzler, K. W. (2004) · Nature Medicine · doi:10.1038/nm1087 · Cited by 4,249 · cited 1×
“These pathways coordinately defend cells from the oncogenic and/or genotoxic stimuli that can lead to malignant transformatio”
BackgroundHOW CELLS RESPOND TO INTERFERONS
Stark, G. R., Kerr, I. M., Williams, B. R. G., Silverman, R. H., & Schreiber, R. D. (1998) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.67.1.227 · Cited by 3,932 · cited 1×
“Detailed reviews of IFN biology have been published elsewher”
BackgroundSelf-citationMechanisms of type-I- and type-II-interferon-mediated signalling
Platanias, L. C. (2005) · Nature Reviews Immunology · doi:10.1038/nri1604 · Cited by 3,491
The Three Es of Cancer Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104803 · Cited by 3,072
Self-citationThe Immunobiology of Cancer Immunosurveillance and Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Immunity · doi:10.1016/j.immuni.2004.07.017 · Cited by 3,032
Self-citationIFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
Shankaran, V., Ikeda, H., Bruce, A. T., White, J. M., Swanson, P. E., Old, L. J., & Schreiber, R. D. (2001) · Nature · doi:10.1038/35074122 · Cited by 2,896
Self-citation
Research works printed but not linked: 1
- Yang, J., Murphy, T. L., Ouyang, W. & Murphy, K. M. Induction of interferon-γ production in TH1 CD4+ T cells: evidence for two distinct pathways for promoter activation. Eur. J. Immunol. 29, 548–555 (1999). · DOI · Paper page
Cited by
Items 701–800 of 1,002
TYK2 in Cancer Metastases: Genomic and Proteomic Discovery
Borcherding, D. C., He, K., Amin, N. V., & Hirbe, A. C. (2021) · Cancers · doi:10.3390/cancers13164171 · Cited by 38
Chemical Metabolic Inhibitors for the Treatment of Blood-Borne Cancers
Villalba, M., López-Royuela, N., Krzywińska, E., Rathore, M. G., Hipskind, R. A., Haouas, H., & Allende-Vega, N. (2014) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/18715206113136660374 · Cited by 35
“Ten years ago, the “old” idea that the immune system could fight against tumors started receiving special attention [1, 2].”
BackgroundGerard, C. M., Baudson, N., Ory, T., & Louahed, J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0094883 · Cited by 34
“It is not the first time that a critical role is attributed to IFN-c in controlling tumor growth (for review see [34]).”
Chaperone-Mediated Autophagy in the Liver: Good or Bad?
Dash, S., Aydın, Y., & Moroz, K. (2019) · Cells · doi:10.3390/cells8111308 · Cited by 33
TYK2 in Tumor Immunosurveillance
Karjalainen, A., Shoebridge, S., Krunic, M., Simonović, N., Tebb, G., Macho‐Maschler, S., Strobl, B., & Müller, M. M. (2020) · Cancers · doi:10.3390/cancers12010150 · Cited by 34
Wenzel, J., Tomiuk, S., Zahn, S., Küsters, D., Vahsen, A., Wiechert, A., Mikus, S., Birth, M., Scheler, M., von Bubnoff, D., et al. (2008) · International Journal of Cancer · doi:10.1002/ijc.23799 · Cited by 32
“Importantly, our analyses revealed the induction of an IFN-associated host immune-response in SCC and to a lesser extent in BCC which may participate in tumor immunosurveillance in the skin.(22)”
Teng, H., Wang, T.-Y., Lin, C., Tong, Z.-J., Cheng, H.-W., & Wang, H. (2024) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-23-0744 · Cited by 32
Mladenova, D. N., & Kohonen‐Corish, M. R. J. (2012) · PubMed · Cited by 38
High expression of soluble CD155 in estrogen receptor-negative breast cancer
Iguchi‐Manaka, A., Okumura, G., Ichioka, E., Kiyomatsu, H., Ikeda, T., Bando, H., Shibuya, A., & Shibuya, K. (2019) · Breast Cancer · doi:10.1007/s12282-019-00999-8 · Cited by 31
Yan, J., Chen, Y., Patel, A. J., Warda, S., Lee, C. J., Nixon, B. G., Wong, E. W. P., Miranda-Román, M. A., Yang, N., Wang, Y., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci153437 · Cited by 33
“IFN-γ is an established key regulator of antigen presentation and chemokine for immune cell recruitment (35, 36).”
BackgroundShields, N. J., Peyroux, E. M., Ferguson, A. L., Steain, M. C., Neumann, S., & Young, S. L. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1152035 · Cited by 33
“PD-L1 can be constitutively expressed by tumour cells or induced by exposure to interferons – in particular IFN-g produced by tumour-specific T cells (46, 47).”
BackgroundSmart drug delivery systems to overcome drug resistance in cancer immunotherapy
Yi, W., Yan, D., Wang, D., & Li, Y. (2023) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2023.0009 · Cited by 32
New Perspectives in Glioma Immunotherapy
Daga, A., Bottino, C., Castriconi, R., Gangemi, R. M. R., & Ferrini, S. (2011) · Current Pharmaceutical Design · doi:10.2174/138161211797249206 · Cited by 33
“Indeed, the hematopoietic compartment of the host is necessary for IFNs antitumor activity, suggesting that the crucial target of IFNs is the immune system [312].”
BackgroundMarciello, M., Pellico, J., Fernández‐Barahona, I., Herranz, F., Ruíz-Cabello, J., & Filice, M. (2016) · Interface Focus · doi:10.1098/rsfs.2016.0055 · Cited by 32
Tgf-beta in the natural history of prostate cancer
Ahel, J. (2019) · Acta Clinica Croatica · doi:10.20471/acc.2019.58.01.17 · Cited by 30
Liang, J., Jin, X., Deng, X., Huang, Q., Zhang, S., Chen, W., & Zhang, X. (2024) · Materials Today · doi:10.1016/j.mattod.2024.07.004 · Cited by 32
Lim, K. H. J., Telisinghe, P. U., Abdullah, M. S., & Ramasamy, R. (2010) · PubMed · Cited by 30
Owen, K. L., & Parker, B. S. (2017) · Molecular Immunology · doi:10.1016/j.molimm.2017.11.023 · Cited by 31
Grainyhead-like-2 confers NK-sensitivity through interactions with epigenetic modifiers
MacFawn, I., Wilson, H. E., Selth, L. A., Leighton, I. A., Serebriiskii, I. G., Bleackley, R. C., Elzamzamy, O. M., Farris, J. C., Pifer, P. M., Richer, J. K., et al. (2018) · Molecular Immunology · doi:10.1016/j.molimm.2018.11.006 · Cited by 31
Fiani, M. L., Barreca, V., Sargiacomo, M., Ferrantelli, F., Manfredi, F., & Federico, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176318 · Cited by 30
Brain cancer immunoediting: novel examples provided by immunotherapy of malignant gliomas
Pellegatta, S., Cuppini, L., & Finocchiaro, G. (2011) · Expert Review of Anticancer Therapy · doi:10.1586/era.11.102 · Cited by 31
Pharmacological Modulation of Anti-Tumor Immunity Induced by Oncolytic Viruses
Forbes, N. E., Krishnan, R., & Diallo, J. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00191 · Cited by 32
Lüth, S., Schrader, J., Zander, S., Carambia, A., Buchkremer, J., Huber, S., Reifenberg, K., Yamamura, K., Schirmacher, P., Lohse, A. W., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3232 · Cited by 33
“Our findings further indicate that inflammatory IFN-g/STAT1 signaling to damaged cells, in addition to indirectly activating cancer immune surveillance (12), may also directly activate the cell-intrinsic p53 tumor suppressor pathway.”
BackgroundInfluentialThompson, L. J., Lai, J.-F., Valladao, A. C., Thelen, T. D., Urry, Z., & Ziegler, S. F. (2016) · Nature Immunology · doi:10.1038/ni.3329 · Cited by 32
Waibler, Z., Detje, C. N., Bell, J. C., & Kalinke, U. (2007) · Immunobiology · doi:10.1016/j.imbio.2007.09.003 · Cited by 34
Tumor-derived death receptor 6 modulates dendritic cell development
DeRosa, D. C., Ryan, P. J., Okragly, A. J., Witcher, D. R., & Benschop, R. J. (2007) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-007-0413-1 · Cited by 33
“In recent years, there has been a growing appreciation for the complex and dynamic interactions between the immune system and emerging tumor cells [3].”
BackgroundNallar, S. C., Kalakonda, S., Lindner, D. J., Lorenz, R. R., Lamarre, E., Weihua, X., & Kalvakolanu, D. V. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.440610 · Cited by 29
Guan, Y., Chen, J., Guan, H., Chen, T.-T., Teng, Y., Wei, Z., Li, Z., Ouyang, S., & Chen, X. (2024) · The Journal of Immunology · doi:10.4049/jimmunol.2300651 · Cited by 29
Testing the theory of immune selection in cancers that break the rules of transplantation
Fassati, A., & Mitchison, N. A. (2009) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-009-0809-1 · Cited by 29
“IDO indoleamine-2,3-dioxygenase [79, 80] Immuno-regulatory”
Samiei, H., Sadighi‐Moghaddam, B., Mohammadi, S., Gharavi, A., Abdolmaleki, S., Khosravi, A., Kokhaei, P., Bazzazi, H., & Memarian, A. (2019) · Immunologic Research · doi:10.1007/s12026-019-09079-7 · Cited by 29
Chi, J., Jiang, Z., Chen, X., Peng, Y., Liu, W., Han, B., & Han, B. (2019) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2019.115297 · Cited by 29
Ludovini, V., Bianconi, F., Siggillino, A., Vannucci, J., Baglivo, S., Berti, V., Tofanetti, F. R., Reda, M. S., Bellezza, G., Mandarano, M., et al. (2021) · Genes · doi:10.3390/genes12020273 · Cited by 29
Padma, A. M., Alshaikh, A. B., Song, M. J., Akouri, R., Oltean, M., Brännström, M., & Hellström, M. (2021) · Journal of Tissue Engineering and Regenerative Medicine · doi:10.1002/term.3217 · Cited by 30
Recent advance in nanomaterials for cancer immunotherapy
Hou, Y., Liu, Y., Tang, C., Tan, Y., Zheng, X., Deng, Y., He, N., & Li, S. (2021) · Chemical Engineering Journal · doi:10.1016/j.cej.2021.134145 · Cited by 29
Axin1 Protects Colon Carcinogenesis by an Immune-Mediated Effect
Sanson, R., Lazzara, S. L., Cune, D., Pitasi, C. L., Trentesaux, C., Fraudeau, M., Letourneur, F., Saintpierre, B., Gall, M. L., Bossard, P., et al. (2022) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2022.10.017 · Cited by 30
“Stat1 plays a vital role in IFNg signaling and is essential for Th1 cell differentiation.(25) Collectively, these results suggest a downregulation of the IFNg/STAT1/Th1 immune response in the tumors of Axin1 mice.”
BackgroundMcLeod, V. M., Chan, L. J., Ryan, G. M., Porter, C. J. H., & Kaminskas, L. M. (2015) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.24353 · Cited by 29
The challenge of selecting the ‘right’ in vivo oncology pharmacology model
Firestone, B. (2010) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2010.06.012 · Cited by 30
Immunotherapy of Metastatic Colorectal Cancer: Prevailing Challenges and New Perspectives
Zumwalt, T. J., & Goel, A. (2015) · Current Colorectal Cancer Reports · doi:10.1007/s11888-015-0269-2 · Cited by 30
Stimulating natural killer cells to protect against cancer: recent developments
Gillgrass, A. E., & Ashkar, A. A. (2011) · Expert Review of Clinical Immunology · doi:10.1586/eci.10.102 · Cited by 32
Starr, R., Fuchsberger, M., Lau, L. S., Uldrich, A. P., Goradia, A., Willson, T. A., Verhagen, A. M., Alexander, W. S., & Smyth, M. J. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0901010 · Cited by 35
Chen, Y., Gao, X.-J., Deng, Y., & Zhang, H. (2011) · Biomarkers · doi:10.3109/1354750x.2011.633242 · Cited by 29
“Third, variants that no longer respond to the host immune system are maintained (Carosella et al.2007, Dunn et al.2006, Dunn et al.2004).”
BackgroundTaipale, K., Liikanen, I., Juhila, J., Turkki, R., Tähtinen, S., Kankainen, M., Vassilev, L., Ristimaki, A. P., Koski, A., Kanerva, A., et al. (2015) · Molecular Therapy · doi:10.1038/mt.2015.143 · Cited by 30
Novel immunotherapy in the treatment of advanced non-small cell lung cancer
Santabarbara, G., Maione, P., Rossi, A., Palazzolo, G., & Gridelli, C. (2016) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2016.1236681 · Cited by 33
“Indeed the inflammatory response induced by cancer cells leads to secretion of cytokines, such as interferon-gamma (IFN-gamma) by T cells, able to stimulate CD8+ T cells and to inhibit tumor progression [20,21].”
BackgroundBonmort, M., Ullrich, E., Mignot, G., Jacobs, B., Chaput, N., & Zitvogel, L. (2007) · Biochimie · doi:10.1016/j.biochi.2007.04.014 · Cited by 29
Saigí, M., Mesía-Carbonell, O., Barbie, D. A., & Guillamat‐Prats, R. (2023) · Cancers · doi:10.3390/cancers15235706 · Cited by 203
“It binds to its receptors IFNGR1 and IFNGR2, activating Janus kinases (JAK1 and JAK2) and the signal transducer and activator of transcription 1 (STAT1) [106].”
BackgroundA STAT3–STING–IFN axis controls the metastatic spread of small cell lung cancer
Guanizo, A. C., Luong, Q., Jayasekara, W. S. N., de Geus, E. D., Inampudi, C., Xue, V. S., Chen, J., de Weerd, N. A., Matthews, A. Y., Gantier, M. P., et al. (2024) · Nature Immunology · doi:10.1038/s41590-024-02014-5 · Cited by 29
“Originally characterized as antiviral molecules, type I IFNs have long been recognized as critical modulators of tumor–immune interactions critical for tumor immunosurveillance 43 .”
Nunney, L. (2020) · Evolutionary Applications · doi:10.1111/eva.12993 · Cited by 29
Complement and Cancer—A Dysfunctional Relationship?
Thurman, J. M., Laskowski, J., & Nemenoff, R. A. (2020) · Antibodies · doi:10.3390/antib9040061 · Cited by 29
Understanding the Immune-Stroma Microenvironment in B Cell Malignancies for Effective Immunotherapy
Apollonio, B., Ioannou, N., Papazoglou, D., & Ramsay, A. G. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.626818 · Cited by 31
“As discussed earlier, there is substantial evidence demonstrating that type I and II IFN signaling is required within TMEs to prevent development of an immunosuppressive state (37, 49).”
BackgroundAlmost famous: Human adenoviruses (and what they have taught us about cancer)
Tessier, T. M., Dodge, M. J., MacNeil, K. M., Evans, A. M., Prusinkiewicz, M. A., & Mymryk, J. S. (2021) · Tumour Virus Research · doi:10.1016/j.tvr.2021.200225 · Cited by 30
Hii, L., Chung, F. F., Mai, C., Ng, P. Y., & Leong, C. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.748470 · Cited by 32
Role of Hypoxia in the Interferon Response
Arnaiz, E., & Harris, A. L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.821816 · Cited by 30
“This is achieved by recognizing tumor-cell-expressed ligands for the NK cell receptor Natural killer group 2 member D (NKG2D), which are induced by genotoxic stress, the generated inflammation or the transformation process itself (71), or tumor-specific antigens presented by antigen presenting cells (72).”
BackgroundKalakonda, S., Nallar, S. C., Gong, P., Lindner, D. J., Goldblum, S. E., Reddy, S. P., & Kalvakolanu, D. V. (2007) · American Journal Of Pathology · doi:10.2353/ajpath.2007.070241 · Cited by 30
“The interferon (IFN) family of cytokines regulate development of neoplasia(1) by acting as a tumor surveillance system in vivo.(2) It has been shown in preclinical and clinical studies(3) that IFN-induced tumor growth suppression is augmented by differentiation inducers, such as the retinoids,(4,5) a class of vitamin…”
BackgroundSTING-dependent cytosolic DNA sensor pathways regulate NKG2D ligand expression
Bert, N. L., Lam, A. R., Ho, S. S. W., Shen, Y. J., Liu, M., & Gasser, S. (2014) · OncoImmunology · doi:10.4161/onci.29259 · Cited by 28
“In addition to enhancing the anti-tumor responses of NK cells, type I IFNs are also critical for enabling cross-presentation of tumor antigens by dendritic cells.(10) In summary, our data suggest that the presence of cytosolic DNA in tumor cells may activate anti-viral immune pathways leading to recognition and lysis…”
BackgroundRuf, B., Berchtold, S., Venturelli, S., Burkard, M., Smirnow, I., Prenzel, T., Henning, S. W., & Lauer, U. M. (2015) · Molecular Therapy — Oncolytics · doi:10.1038/mto.2015.19 · Cited by 28
Rivero, I. B., García-Vega, Y., Duncan-Roberts, Y., Vazquez-Blomquistc, D., Santana-Milián, H., Besada, V., & Rios-Cabrera, M. (2018) · Seminars in Oncology · doi:10.1053/j.seminoncol.2018.04.007 · Cited by 35
SIDT2 RNA Transporter Promotes Lung and Gastrointestinal Tumor Development
Nguyen, T. A., Bieging-Rolett, K. T., Putoczki, T. L., Wicks, I. P., Attardi, L. D., & Pang, K. C. (2019) · iScience · doi:10.1016/j.isci.2019.09.009 · Cited by 29
“…unable to detect upregulation of Ifn b or various IFN-stimulated genes in tissues of Apc min/+ ;Sidt2 (cid:1) / (cid:1) mice (data not shown), suggesting that the reduced tumor burden observed in SIDT2-deficient mice is unlikely to be due to the anti-tumor effects of type I IFN (Dunn et al., 2006).”
BackgroundInfluentialInterferon‐gamma carrying nanoemulsion with immunomodulatory and anti‐tumor activities
Ribeiro, E. B., de Marchi, P. G. F., Honório‐França, A. C., França, E. L., & Soler, M. A. G. (2019) · Journal of Biomedical Materials Research Part A · doi:10.1002/jbm.a.36808 · Cited by 29
Li, X., Luo, L., Jiang, M., Zhu, C., Shi, Y., Zhang, J., Qin, B., Luo, Z., Guo, X., Lu, Y., et al. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.05.002 · Cited by 29
Stricker, T. P., & KUMAR, V. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4377-0792-2.50012-2 · Cited by 62
Immunity and the Emergence of Individuality
Pradeu, T. (2013) · The MIT Press eBooks · doi:10.7551/mitpress/8921.003.0008 · Cited by 38
Galor, A., Garg, N., Nanji, A., Joag, M. G., Nuovo, G. J., Palioura, S., Wang, G., & Karp, C. L. (2015) · Ophthalmology · doi:10.1016/j.ophtha.2015.07.007 · Cited by 28
NF-κB Fans the Flames of Lung Carcinogenesis
Wong, K., Jacks, T., & Dranoff, G. (2010) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-10-0042 · Cited by 28
“A predominance of IFN-α and IFN-γ release by cancer cells and stromal elements may elicit a protective reaction through the combined effects of enhancing tumor cell immunogenicity and stimulating lymphocyte-mediated cytotoxicity (11, 12, 20).”
BackgroundImpaired anti-leukemic immune response in PKCθ-deficient mice
Garaude, J., Kaminski, S., Charni, S., Aguilò, J. I., Jacquet, C., Plays, M., Hernández, J., Rodríguez, F., Hipskind, R. A., Anel, A., et al. (2008) · Molecular Immunology · doi:10.1016/j.molimm.2008.03.016 · Cited by 29
IFNγ enhances cytotoxic efficiency of the cytotoxic T lymphocytes against human glioma cells
Shao, S., Risch, E., Burner, D., Lu, L., Minev, B., & Ma, W. (2017) · International Immunopharmacology · doi:10.1016/j.intimp.2017.04.003 · Cited by 27
Matsushita, H., Hasegawa, K., Oda, K., Yamamoto, S., Nishijima, A., Imai, Y., Asada, K., Ikeda, Y., Karasaki, T., Fujiwara, K., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1338996 · Cited by 28
Stasikowska‐Kanicka, O., Wągrowska‐Danilewicz, M., & Danilewicz, M. (2017) · Journal of Oral Pathology and Medicine · doi:10.1111/jop.12657 · Cited by 28
IFN-γ is a therapeutic target in paraneoplastic cerebellar degeneration
Yshii, L., Pignolet, B., Mauré, E., Pierau, M., Brunner-Weinzierl, M. C., Hartley, O., Bauer, J., & Liblau, R. (2019) · JCI Insight · doi:10.1172/jci.insight.127001 · Cited by 28
“Importantly, IFN-γ is an essential effector cytokine for tumor immune rejection, and loss of IFN-γ production by T cells allows tumor growth and persistence (40).”
BackgroundProgrammed cell death ligand‐1: A dynamic immune checkpoint in cancer therapy
Kalim, M., Khan, M. S. I., & Zhan, J. (2020) · Chemical Biology & Drug Design · doi:10.1111/cbdd.13677 · Cited by 27
Chanukuppa, V., Taware, R., Taunk, K., Chatterjee, T., Sharma, S., Somasundaram, V., Rashid, F., Malakar, D., Santra, M. K., & Rapole, S. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.566804 · Cited by 28
“During the tumor progression, various innate immunity components are activated to minimize the inflammation caused by cancer (54, 55).”
BackgroundTan, Y., Huang, J., Li, Y., Li, S., Luo, M., Luo, J., Lee, A. W. M., Fu, L., Hu, F., & Guan, X. (2021) · Advanced Healthcare Materials · doi:10.1002/adhm.202101496 · Cited by 27
Microbial metabolites and immunotherapy: Basic rationale and clinical indications
Kovtonyuk, L. V., & McCoy, K. D. (2023) · Seminars in Immunology · doi:10.1016/j.smim.2023.101755 · Cited by 27
Update of cellular responses to the efferocytosis of necroptosis and pyroptosis
Purnama, C. A., Meiliana, A., Barliana, M. I., & Lestari, K. (2023) · Cell Division · doi:10.1186/s13008-023-00087-6 · Cited by 28
“When a tumour is forming, for example, dying cells may still be harmful to the body and may be eliminated by the host immune system [21].”
BackgroundOtegui, N., Houry, M., Arozarena, I., Serrano, D., Redín, E., Expósito, F., León, S., Valencia, K., Montuenga, L. M., & Calvo, A. (2023) · Cancers · doi:10.3390/cancers15123076 · Cited by 30
Tumor antigens in human cancer control
Kelderman, S., & Kvistborg, P. (2015) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2015.10.004 · Cited by 29
Borden, E. C., Jacobs, B., Hollovary, E., Rybicki, L. A., Elson, P. J., Olencki, T. E., & Triozzi, P. L. (2011) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2010.0054 · Cited by 30
Clinical evaluation of cellular immunotherapy in acute myeloid leukaemia
Smits, E., Lee, C., Hardwick, N. R., Brooks, S. E., Tendeloo, V. F. V., Orchard, K. H., & Guinn, B. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1022-6 · Cited by 33
“Strikingly, in response to electroporation with poly(I:C) all AML cell samples produced type I interferons, known for their antitumoural effects [80, 81].”
BackgroundSpontaneous immune responses to sporadic tumors: tumor-promoting, tumor-protective or both?
de Visser, K. E. (2008) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-008-0501-x · Cited by 32
“Likewise, chemical-induced cancer might similarly be more easily prevented by adaptive immune responses than tumors initiated by genetic alterations [18, 47].”
BackgroundWu, S., Xing, W., Peng, J., Yuan, X., Zhao, X., Lei, P., Li, W., Wang, M., Zhu, H., Huang, B., et al. (2007) · Immunobiology · doi:10.1016/j.imbio.2007.10.003 · Cited by 27
New and Experimental Skin-Directed Therapies for Cutaneous Lymphomas
Farkas, Á., Kemény, L. V., French, L. E., & Dummer, R. (2009) · Skin Pharmacology and Physiology · doi:10.1159/000241302 · Cited by 27
“The case reports cited above and pilot studies demonstrated that imiquimod might be effective in some cases with therapy-resistant lesions of CTCL as well as of CBCL with an acceptable safety profile (table 4 ). TG-1042 Adenovirus VectorIFN-γ is a cytokine with immunostimulatory, antitumour, antiproliferative and anti…”
ResultPrognosis Relevance of Serum Cytokines in Pancreatic Cancer
Torres, C., Linares, A., Alejandre, M. J., Palomino‐Morales, R., Caba, O., Prados, J. C., Aránega, A., Delgado, J. R., Irigoyen, A., Martínez-Galán, J., et al. (2015) · BioMed Research International · doi:10.1155/2015/518284 · Cited by 27
“A dynamic relationship between the host immune system and cancer is emerging [62].”
BackgroundGranzyme B–Mediated Damage of CD8+ T Cells Impairs Graft-versus-Tumor Effect
Bian, G., Ding, X., Leigh, N. D., Tang, Y., Capitano, M. L., Qiu, J., McCarthy, P. L., Liu, H., & Cao, X. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1201554 · Cited by 27
Klepsch, V., Hermann‐Kleiter, N., & Baier, G. (2016) · Immunology Letters · doi:10.1016/j.imlet.2016.03.007 · Cited by 29
Namjoshi, P., Showalter, L., Czerniecki, B. J., & Koski, G. K. (2016) · Oncotarget · doi:10.18632/oncotarget.10298 · Cited by 27
“com losses of HER-2 expression to be a special vaccine-induced form of the “immunoediting” phenomenon described previously by others [11, 12]; HER-2-specific CTL were presumably destroying the HER-2-overexpressing cell population within heterogeneous tumor masses and thus selecting for a residuum of disease that was H…”
BackgroundNK1.1+ Cells and CD8+ T Cells Mediate the Antitumor Activity of Cl-IB-MECA in a Mouse Melanoma Model
Morello, S., Sorrentino, R., Montinaro, A., Luciano, A., Maiolino, P., Ngkelo, A., Arra, C., Adcock, I. M., & Pinto, A. (2011) · Neoplasia · doi:10.1593/neo.101628 · Cited by 28
“NK Cells Are Essential for Cl-IB-MECA Antitumor Activity TNF-α and IFN-γ play an important role in both innate and acquired immunity [22] and are released from both NK cells and CD8 T cells [23–25].”
BackgroundUse of systemic glucocorticoids and the risk of colorectal cancer
Ostenfeld, E. B., Erichsen, R., Thorlacius‐Ussing, O., Riis, A. H., & Sørensen, H. T. (2012) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12115 · Cited by 30
Danish, H. H., Goyal, S., Taunk, N. K., Wu, H., Moran, M. S., & Haffty, B. G. (2013) · The Breast Journal · doi:10.1111/tbj.12097 · Cited by 26
Expression and Prognostic Value of IFIT1 and IFITM3 in Head and Neck Squamous Cell Carcinoma
Li, H., Yang, L., Wu, C., Xiao, Y., Mao, L., Chen, L., Zhang, W., & Sun, Z. (2019) · American Journal of Clinical Pathology · doi:10.1093/ajcp/aqz205 · Cited by 27
Sakatani, T., Kita, Y., Fujimoto, M., Sano, T., Hamada, A., Nakamura, K. D., Takada, H., Goto, T., Sawada, A., Akamatsu, S., et al. (2022) · Cancers · doi:10.3390/cancers14020263 · Cited by 28
Tseng, S.-H., Cheng, M. A., Farmer, E. A., Ferrall, L., Kung, Y. J., Lam, B. K., Lim, L., Wu, T. ‐., & Hung, C. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004342 · Cited by 27
Navigating the Cytokine Seas: Targeting Cytokine Signaling Pathways in Cancer Therapy
Stanilov, N., Velikova, T. V., & Stanilova, S. A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25021009 · Cited by 29
“Chronic inflammation upregulates several proinflammatory cytokines, mainly IL-1, TNF-α , IFN-γ , IL-6, IL-12, IL-23, and IL-17, involved in both the initiation and progression of cancer [6–9].”
BackgroundCD80-CD28 signaling controls the progression of inflammatory colorectal carcinogenesis
Scarpa, M., Brun, P., Scarpa, M., Morgan, S., Porzionato, A., Kotsafti, A., Bortolami, M., Buda, A., Renata D'Incà, Macchi, V., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.2780 · Cited by 28
“These observations suggest the presence of efficient immune surveillance mechanisms that lead to neoplastic cells destruction (immune surveillance), possibly mediated by T-cells, macrophages, and natural killer cells [11].”
Buferne, M., Chasson, L., Grange, M., Mas, A., Arnoux, F., Bertuzzi, M., Naquet, P., Leserman, L., Schmitt‐Verhulst, A., & Auphan‐Anezin, N. (2015) · OncoImmunology · doi:10.4161/2162402x.2014.974959 · Cited by 27
“IFNg has been shown to enhance the MHC-I antigen processing and presentation pathway.(22,23) However, IFNg was also found to up-regulate expression of immunosuppressive ligands such as PDL-1 on tumor cells, including melanomas.”
BackgroundShi, X., Li, Q., Liu, G., Zhao, S., Peng, N., & Chen, X. (2008) · Cellular and Molecular Immunology · doi:10.1038/cmi.2008.42 · Cited by 29
“inflammatory cytokine (TGF-β and IL-10) responses (26).”
BackgroundMethodZhao, D.-X., Li, Z., Zhang, Y., Zhang, X., Zhao, K.-C., Li, Y., Zhang, M., Yu, X., Liu, M.-Y., & Li, Y. (2014) · Cellular Immunology · doi:10.1016/j.cellimm.2014.03.020 · Cited by 27
Dong, Q., Sugiura, T., Toyohira, Y., Yoshida, Y., Yanagihara, N., & Karasaki, Y. (2010) · Phytomedicine · doi:10.1016/j.phymed.2010.06.008 · Cited by 29
“FN- exerts antiviral effects in several diseases and is beneficial gainst some types of cancers (Dunn et al., 2006).”
BackgroundThe role of Type I interferons in immunoregulation of breast cancer metastasis to the bone
Slaney, C. Y., Möller, A., Hertzog, P. J., & Parker, B. S. (2012) · OncoImmunology · doi:10.4161/onci.22339 · Cited by 29
Kim, Y., Kim, S., Hwang, D. Y., Jang, J. E., Hyun, S. Y., Kim, Y. R., Kim, J. S., Min, Y. H., & Cheong, J. (2014) · Yonsei Medical Journal · doi:10.3349/ymj.2014.55.6.1568 · Cited by 27
Surgery-induced tumor growth in (metastatic) colorectal cancer
Govaert, K. M., Jongen, J. M. J., Kranenburg, O., & Rinkes, I. H. M. B. (2017) · Surgical Oncology · doi:10.1016/j.suronc.2017.10.004 · Cited by 28
Cytotoxic Pathways in Allogeneic Hematopoietic Cell Transplantation
Du, W., & Cao, X. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02979 · Cited by 30
Metadata
- Authors
- Dunn, G. P., Koebel, C. M., & Schreiber, R. D.
- Affiliations
- Washington University in St. Louis (US)
- Corresponding author
- Schreiber, Robert D.
- Venue
- Nature Reviews Immunology
- Published
- 2006-11
- Volume
- 6
- Issue
- 11
- Pages
- 836-848
- ISSN
- 1474-1733 (ISSN-L)
- 1474-1741
- OpenAlex
- W2052313621
- Cited by
- 1,617
- References
- 119
- Citations by year
- 2026: 33 · 2025: 51 · 2024: 87 · 2023: 104 · 2022: 84 · 2021: 94 · 2020: 93 · 2019: 73 · 2018: 85 · 2017: 74 · 2016: 93 · 2015: 100 · 2014: 100 · 2013: 79 · 2012: 76
- FWCI
- 4.99
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Immunology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › interferon and immune responses
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- interferon, type I interferon, interferon-gamma, cancer immunoediting, tumor surveillance, antitumor immunity, tumor-immune interactions, interferon-alpha, interferon-beta, cancer immunotherapy
- MeSH terms
- Animals, Humans, Immunity, Immunotherapy, Interferons, Neoplasms, Monitoring, Immunologic, Signal Transduction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.